Rituximab-2cda + Rituximab maintenance in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Rituximab (Primary) ; Cladribine
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 28 Sep 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 03 Oct 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 03 Oct 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).